Brinavess is a medicine used to rapidly restore normal heart rhythm in adult patients who have recently started having atrial fibrillation. Atrial fibrillation happens when the atria (the upper chambers of the heart) contract irregularly and rapidly, resulting in abnormal heart rhythm. Brinavess is to be used for atrial fibrillation that has started within the last seven days, or within the last three days if the patient had recently had heart surgery.
Brinavess contains the active substance vernakalant hydrochloride.
Brinavess : EPAR - Medicine overview (PDF/88.29 KB)
First published: 28/09/2010
Last updated: 14/11/2019
Brinavess : EPAR - Risk-management-plan summary (PDF/288.4 KB)
First published: 19/12/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
15 rue du Bicentenaire
02/03/2022 Brinavess - EMEA/H/C/001215 - N/0040
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults:
- for non-surgery patients: atrial fibrillation </= 7 days duration;
- for post-cardiac surgery patients: atrial fibrillation </= 3 days duration.